Detalles de la búsqueda
1.
Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma.
Clin Nucl Med;
49(4): e149-e155, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38350067
2.
Intricacies in the Preparation of Patient Doses of [177Lu]Lu-Rituximab and [177Lu]Lu-Trastuzumab Using Low Specific Activity [177Lu]LuCl3: Methodological Aspects.
Mol Imaging Biol;
26(1): 61-80, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37673943
3.
Evaluation of Different Methods for the Detection of Anti- Thyroglobulin Autoantibody: Prevalence of Anti-Thyroglobulin Autoantibody and Anti-Microsomal Autoantibody in Thyroid Cancer Patients.
Indian J Clin Biochem;
37(4): 473-479, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36262779
4.
Clinical Dose Preparation of [177Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [177Lu]LuCl3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression.
Cancer Biother Radiopharm;
37(5): 384-402, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35575711
5.
Automated radiochemical synthesis of pharmaceutical grade [18 F]FLT using 3-N-Boc-5'-O-dimethoxytrityl-3'-O-nosyl-thymidine precursor and its Sep-Pak® purification employing selective elution from reversed phase.
J Labelled Comp Radiopharm;
65(8): 206-222, 2022 06 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35466460
6.
Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[177Lu]Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [177Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles.
Cancer Biother Radiopharm;
37(3): 214-225, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-34910891
7.
Prospective evaluation of organ-specific dose and lesional doses following therapeutic [177Lu]Lu-EDTMP administration in patients with multiple skeletal metastases and its correlation with clinical hematological toxicity.
Nucl Med Commun;
42(10): 1076-1084, 2021 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34528928
8.
Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy.
Cancer Biother Radiopharm;
36(8): 682-692, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34402687
9.
Initial clinical evaluation of indigenous 90Y-DOTATATE in sequential duo-PRRT approach (177Lu-DOTATATE and 90Y-DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, 90Y-DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects.
World J Nucl Med;
20(1): 73-81, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33850492
10.
On the Separation of Yttrium-90 from High-Level Liquid Waste: Purification to Clinical-Grade Radiochemical Precursor, Clinical Translation in Formulation of 90Y-DOTATATE Patient Dose.
Cancer Biother Radiopharm;
36(2): 143-159, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33750229
11.
Production, characterization and in-vitro applications of single-domain antibody against thyroglobulin selected from novel T7 phage display library.
J Immunol Methods;
492: 112990, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33561431
12.
Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy.
Cancer Biother Radiopharm;
36(3): 292-304, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32379495
13.
One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [177Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting.
Am J Nucl Med Mol Imaging;
10(4): 178-211, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32929396
14.
Clinical Efficacy of Sodium [99mTc] Pertechnetate from Low Specific Activity 99Mo/99mTc Autosolex Generator in Hospital Radiopharmacy Centre.
Nucl Med Rev Cent East Eur;
23(1): 1-14, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32779168
15.
Surface modified silk fibroin nanoparticles for improved delivery of doxorubicin: Development, characterization, in-vitro studies.
Int J Biol Macromol;
164: 2018-2027, 2020 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32758604
16.
Sequential Duo-Peptide Receptor Radionuclide Therapy With Indigenous 90Y-DOTATATE and 177Lu-DOTATATE in Large-Volume Neuroendocrine Tumors: Posttherapy Bremsstrahlung and PET/CT Imaging Following 90Y-DOTATATE Treatment.
Clin Nucl Med;
45(9): 714-715, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32657872
17.
Availability of both [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTATATE as PRRT agents for neuroendocrine tumors: can we evolve a rational sequential duo-PRRT protocol for large volume resistant tumors?
Eur J Nucl Med Mol Imaging;
47(4): 756-758, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31628515
18.
Towards personalizing treatment strategies in mCRPC: can dual-tracer PET-CT provide insights into tumor biology, guide the optimal treatment sequence, and individualize decision-making (between chemotherapy, second-generation anti-androgens and PSMA-directed radioligand therapy) early in the disease course?
Eur J Nucl Med Mol Imaging;
47(8): 1793-1797, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31776630
19.
Clinical utility of 177 Lu-DOTATATE PRRT in somatostatin receptor-positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity.
Head Neck;
42(3): 401-416, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31755622
20.
Comparison of Serum Thyroglobulin Levels in Differentiated Thyroid Cancer Patients Using In-House Developed Radioimmunoassay and Immunoradiometric Procedures.
Indian J Clin Biochem;
34(4): 465-471, 2019 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-31686734